Key clinical point : BCL6 positivity is associated with worse survival outcomes and a higher Ki67 index and shows a positive correlation with CD10 positivity in patients with mantle cell lymphoma (MCL).
Major finding: A positive vs negative expression of BCL6 was associated with a significantly shorter median overall survival (14 vs 43 months; P =.01) and was significantly correlated with CD10 positivity (odds ratio 5.11; P =.0000286) and a higher Ki67 index ( P =.0094).
Study details: The data come from a systematic review and meta-analysis of 10 studies that involved 102 patients with MCL and reported BCL6- and CD10-positive or -negative MCL and Ki67% in BCL6-positive or -negative MCL.
Disclosures: This study received no external funding. The authors declared no conflicts of interest.
Source: Castillo DR et al. Unveiling the prognostic significance of BCL6+/CD10+ mantle cell lymphoma: Meta-analysis of individual patients and systematic review. Int J Mol Sci. 2023;24(12):10207 (Jun 16). Doi: 10.3390/ijms241210207